Summary:
Researchers at the University of Birmingham have found that blocking the P2X7 receptor in human brain tissue directly suppresses harmful neuroinflammation. Published in the journal Brain, the study used living human brain slices obtained during neurosurgery and a scalable model of human monocyte-derived microglia to show that P2X7 inhibition prevents the release of pro-inflammatory cytokines. Because P2X7 antagonists already exist and have been tested in humans, this discovery creates an opportunity to repurpose those drugs quickly for a range of conditions—from traumatic brain injury and multiple sclerosis to Alzheimer’s, Parkinson’s and inflammation-linked psychiatric disorders such as depression and schizophrenia.
Key Facts:
- The P2X7 inflammatory gate: The P2X7 receptor functions as a key trigger of inflammatory signaling in the central nervous system. Selective antagonists sharply reduce the release of destructive cytokines from human microglia and brain tissue.
- Human microglia model: The team converted peripheral blood monocytes into microglia-like cells that retain relevant functional characteristics, overcoming the long-standing problem of primary human microglia losing their identity outside the brain.
- Repurposing potential: Because several P2X7 antagonists have already advanced through clinical testing, these findings provide a near-term translational path to clinical trials for conditions that currently lack targeted anti-inflammatory drugs.
Source: University of Birmingham
Halting the destructive cascade of neuroinflammation
Neuroinflammation is increasingly recognized as a common and damaging factor across many major brain disorders. Whether triggered acutely by mechanical injury such as traumatic brain injury (TBI) or concussion, or developing slowly over decades in neurodegenerative diseases like Alzheimer’s and Parkinson’s, uncontrolled inflammation disrupts synaptic connections, impairs neuronal signaling and accelerates cell loss. Growing evidence also links neuroinflammatory processes to psychiatric conditions, including major depressive disorder and schizophrenia.
Despite this widespread impact, there are currently no targeted treatments that reliably shut down neuroinflammation once it begins in the human central nervous system. The University of Birmingham team has now identified a precise molecular switch—P2X7—that can be targeted to interrupt the inflammatory cascade at its source.
Their work shows that inhibiting P2X7 in living human tissue stops cytokine cascades. Because brain-penetrant P2X7 antagonists already exist and have undergone human safety testing, these results offer a rapid path to repurpose available compounds for clinical trials addressing conditions driven by neuroinflammation.
Overcoming the microglial research hurdle
Microglia are the brain’s resident immune cells, responsible for sensing damage, clearing debris and releasing signaling molecules. Studying them in humans has been difficult because primary human microglia quickly change their gene expression and morphology when removed from the brain, losing the characteristics that make them relevant in disease contexts.
To address this, the researchers developed a reproducible method to differentiate peripheral blood monocytes into microglia-like cells. This approach models the natural process by which blood-derived monocytes can enter the brain and supplement the resident microglial population, particularly with age or injury. The resulting monocyte-derived microglia provide a scalable, physiologically relevant platform for testing human-specific inflammatory responses and pharmacological interventions.
Validating the P2X7 switch in living neurosurgical tissue
Using the monocyte-derived microglia model, the team exposed cells to inflammatory triggers and mapped the molecular pathways involved. They identified the P2X7 receptor as the central driver of microglial cytokine release. P2X7 is activated by extracellular ATP released by injured or dying cells and acts as a danger sensor that engages the inflammasome machinery responsible for producing pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18.
Applying selective P2X7 antagonists halted that cytokine release in a concentration-dependent manner. To confirm these effects were not limited to cultured cells, the researchers tested the antagonists on slices of living human brain tissue obtained during neurosurgical procedures. The antagonists reproduced the anti-inflammatory effect in intact human brain architecture, validating P2X7 as a actionable target in human tissue.
Accelerated path to clinical trials
Developing a new central nervous system drug from scratch typically takes a decade or more and costs many millions. Because P2X7 antagonists have already been through clinical evaluation for safety and pharmacology, repurposing them could bypass major early-stage barriers and shorten the route to patient trials. The research team is preparing clinical protocols to test P2X7 antagonists in patient groups lacking disease-modifying options, including those with TBI and progressive neurodegenerative diseases.
Professor Nicholas Barnes, corresponding author of the study and Professor of Neuropharmacology at the University of Birmingham, emphasized the translational importance: identifying P2X7-mediated responses in both monocyte-derived microglia and human brain tissue supports moving toward clinical testing in conditions where neuroinflammation drives damage and clinical decline.
Editorial notes
- This article was edited by a Neuroscience News editor.
- The referenced journal paper was reviewed in full by the editorial team.
- Additional context was provided by editorial staff to clarify the translational and clinical implications.
About this neurology and neuropharmacology research
- Media contact: Tim Mayo
- Source: University of Birmingham
- Image credit: Image credited to Neuroscience News
- Original research (open access): Brain (Oct 1, 2026). Title: “P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics.” Authors include Jamie Cowley, Neale Harrison, Ashley Pegg, Hujo Chan, Zhi Li, Arshpreet Kaur, Emma Welsh and collaborators across clinical and preclinical neuroscience teams.
Abstract
P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics
Traumatic brain injury remains a leading cause of death and disability worldwide, and there are currently no approved drugs that modify the underlying neuroinflammatory damage that follows injury. Microglial activation and the resulting inflammatory response create a therapeutic window in which pharmacological intervention could reduce secondary damage. The purinergic P2X7 receptor plays a central role in neuroinflammation across animal models of brain injury.
To provide direct translational evidence, the authors optimized two human-based inflammatory models: monocyte-derived microglia in vitro and human brain tissue slices ex vivo. Using lipopolysaccharide-primed human monocyte-derived microglia, the P2X7 agonist BzATP induced concentration-dependent release of IL-1β and IL-18. These responses were antagonized by selective P2X7 inhibitors and by blockers of the NLRP3 inflammasome or caspase-1, implicating inflammasome-dependent cytokine release.
In human brain slices, BzATP also elicited cytokine release that was suppressed by pharmacologically relevant concentrations of P2X7 antagonists. The study demonstrates that central P2X7 antagonism can suppress pro-inflammatory responses in primed human microglia and intact human brain tissue, supporting the potential for clinical benefit in TBI and other neuroinflammatory pathologies.
